Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-16T13:22:39.723Z Has data issue: false hasContentIssue false
  • English
  • Français

Trastorno obsesivo-compulsivo relacionado con el topiramato

Published online by Cambridge University Press:  12 May 2020

Cigdem Ozkara ,
Mine Ozmen ,
Ayten Erdogan  and
Irem Yalug
Cigdem Ozkara
Affiliation:
Departamento de Neurología, Universidad de Estambul, Facultad de Medicina de Cerrahpasa, Cerrahpasa Cad, Kocamustafapasa, 34230, Estambul, Turquía
Mine Ozmen
Affiliation:
Departamento de Psiquiatría, Universidad de Estambul, Facultad de Medicina de Cerrahpasa, Cerrahpasa Cad, Kocamustafapasa, 34230, Estambul, Turquía
Ayten Erdogan
Affiliation:
Departamento de Psiquiatría del Niño y del Adolescente, Universidad de Estambul, Facultad de Medicina de Cerrahpasa, Cerrahpasa Cad, Kocamustafapasa, 34230, Estambul, Turquía
Irem Yalug
Affiliation:
Departamento de Psiquiatría, Universidad Kocaeli, Facultad de Medicina de Kocaeli, Kocaeli, Turquía
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Caso Clínico
Information
European Psychiatry (Ed. Española) , Volume 12 , Issue 6 , September 2005 , pp. 355 - 357
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

[1] Dannon, PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003;26(l):l–4.CrossRefGoogle ScholarPubMed
[2] Hirai, K, Kimiya, S, Tabata, K, Seki, T, Jozaki, K. Selective mutism and obsessive compulsive disorders associated with zonisamide. Seizure 2002; 11:468–70.CrossRefGoogle ScholarPubMed
[3] Kanner, AM, Wuu, J, Faught, E, Tatum, WO, Fix, A, French, JA. A post psychiatric history may be a risk factor for topiramate -related psychiatric and cognitive adverse events. Epilepsy Behav 2003;4(5):548–52.CrossRefGoogle Scholar
[4] Marsh, L, Rao, V. Psychiatric complications in patients with epilepsy: a review. Epilepsy Res 2002;49:11–3.CrossRefGoogle ScholarPubMed
[5] Mathew, NT, Kailasam, J, Meadors, L. Prophylaxis of migraine, transformed migraine and cluster headache with topiramate. Headache 2002;42:796–803.CrossRefGoogle ScholarPubMed
[6] Mula, M, Trimble, MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003;4(3):430–4.CrossRefGoogle ScholarPubMed
[7] Pauls, LD. The role of genetic factors in OCD. In: Fineberg, PN, Marazziti, D, Stein, D, editors. Obsessive compulsive disorder: a practical guide. London: Taylor & Francis; 2001. p. 61-77.Google Scholar
[8] Perucca, E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997;35:241–56.CrossRefGoogle ScholarPubMed
[9] Roy, KN, Chengappa, J, Levine, D, Rathore, H, Parepally, Atzert, R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001;16:186–90.Google Scholar